Can You Get Mounjaro or Wegovy on the NHS? Your Complete 2025 Guide for Women's Weight Loss

‍The Short Answer: Yes, But Access Is Limited

Mounjaro (tirzepatide) and Wegovy (semaglutide) are available on the NHS, but only for patients meeting strict clinical criteria set by the National Institute for Health and Care Excellence (NICE). NHS England estimates approximately 220,000 patients will qualify for these medications across primary care and specialist weight management services. However, the eligibility thresholds differ significantly between the two drugs, with Mounjaro requiring more severe obesity and multiple health complications.^[1][2][3][4]

For women specifically seeking these treatments, understanding the nuanced requirements—including how conditions like PCOS or menopause-related metabolic changes factor into eligibility—is essential for navigating the NHS pathway successfully.

NHS Eligibility Criteria: Mounjaro vs Wegovy

The eligibility criteria for these medications reflect their different approval timelines and clinical positioning within NHS obesity management strategies.

Mounjaro (Tirzepatide) NHS Requirements

Mounjaro received NICE recommendation in December 2024 (TA1026) and represents the newer option on NHS formularies. The eligibility bar is set deliberately high for initial rollout:^[5]

Primary Criteria (Cohort 1: 2025-26):

· BMI of 40 or higher

· Four or more diagnosed weight-related comorbidities from this specific list:^[1][3][6]

o Type 2 diabetes

o Hypertension (high blood pressure)

o Cardiovascular disease

o Obstructive sleep apnoea

o Dyslipidaemia (abnormal blood fats)

Ethnicity Adjustments: For patients from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds, the BMI threshold reduces by 2.5 kg/m² (to BMI ≥37.5).^[7][1]

Wegovy (Semaglutide) NHS Requirements

Wegovy gained NICE approval in March 2023 (TA875) and has broader eligibility criteria:^[2][4]

Primary Criteria:

· BMI of 35 or higher with at least one weight-related comorbidity (hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease)^[2]

· BMI between 30-34.9 may qualify if referred to specialist weight management services and meeting defined criteria^[8][2]

Ethnicity Adjustments: Similar 2.5 kg/m² BMI reduction applies for ethnic minority populations.^[9]

Key Differences at a Glance

‍

NHS Eligibility Criteria Comparison: Mounjaro vs Wegovy

The fundamental distinction lies in severity thresholds: Mounjaro requires both higher BMI (≥40 vs ≥35) and more comorbidities (4+ vs 1+), making it accessible to a smaller, more medically complex patient population during initial rollout.^[1][10]

Understanding BMI and Comorbidity Requirements

BMI Thresholds Explained

Body Mass Index remains the primary screening tool, but the NHS applies different thresholds based on health risk profiles. For Mounjaro, the BMI ≥40 threshold identifies patients with severe obesity (Class III), representing the highest risk category. Wegovy's BMI ≥35 threshold (Class II obesity) captures a larger population with established weight-related health complications.^[2][6]

Important Consideration for Women: BMI doesn't distinguish between muscle and fat mass. Women with PCOS may have altered body composition, and those experiencing menopause often see central fat redistribution. The NHS acknowledges these physiological differences through ethnicity adjustments but doesn't currently have PCOS-specific BMI modifications.^[9]

Required Health Conditions: What Counts?

The comorbidity requirements create a significant barrier for otherwise healthy obese individuals. For Mounjaro, needing four conditions means patients must have multiple diagnosed metabolic or cardiovascular issues.^[1][3]

Qualifying Conditions Include:

· Type 2 diabetes: Particularly relevant for women with PCOS, who have 5-10x higher risk^[4]

· Hypertension: Affects 1 in 4 adults with obesity

· Cardiovascular disease: Includes ischaemic heart disease, stroke history

· Obstructive sleep apnoea: Strongly associated with obesity, especially in women post-menopause

· Dyslipidaemia: Abnormal cholesterol or triglyceride levels

Ethnicity Adjustments: Why They Matter

The NHS applies lower BMI thresholds for ethnic minorities because these populations develop obesity-related complications at lower body weights due to differences in fat distribution and metabolic risk. For example, a woman of South Asian descent with BMI 37.5 would qualify for Mounjaro assessment, whereas a white British woman would need BMI 40+.^[1][7]

How to Access Treatment Through the NHS

Specialist Weight Management Services (Tier 3/4)

Both medications are primarily prescribed through specialist weight management services, not routine GP appointments. These multidisciplinary teams provide:^[11][12]

· Comprehensive metabolic assessment

· Dietary and behavioural support

· Medication initiation and titration

· Ongoing monitoring and follow-up^[11]

The Referral Process:

1. GP Assessment: Your doctor confirms BMI and comorbidities meet criteria

2. Referral Submission: GP refers to local specialist weight management service

3. Specialist Review: Multidisciplinary team assesses suitability

4. Treatment Decision: If approved, medication prescribed through service

5. Shared Care: After stabilization, prescribing may transfer to primary care^[11]

Primary Care Pathways for Mounjaro

From June 2025, NHS England began a phased primary care rollout for Mounjaro, allowing GPs to prescribe directly to eligible patients. However, this remains limited to those meeting the strict BMI ≥40 plus 4+ comorbidities criteria. Practices are advised not to accept patient requests unless eligibility is confirmed.^[1][7][13]

Critical Caveat: GPs cannot prescribe outside NICE guidance, and resources are limited. A typical 6,000-patient practice expects only 15-20 eligible individuals.^[3][1]

Regional Variations

Implementation varies across Integrated Care Systems (ICS). Some regions maintain stricter controls, restricting prescribing to Tier 3/4 services only. Always check your local ICS weight management policy.^[12]

Women's Health Considerations

PCOS and Weight Loss Medications

Polycystic Ovary Syndrome affects 1 in 10 women and is strongly associated with insulin resistance and weight gain. While PCOS itself isn't a listed comorbidity for NHS eligibility, its metabolic consequences often are:

· Type 2 diabetes: PCOS increases risk substantially, potentially qualifying women for treatment^[4]

· Dyslipidaemia: Common in PCOS due to metabolic dysfunction

· Hypertension: Increased risk, especially with obesity

Women with PCOS should ensure these secondary conditions are formally diagnosed and documented, as they count toward the 4+ comorbidity threshold for Mounjaro.

Fertility and Pregnancy Guidance

NHS Fertility Services Exception: Women requiring weight loss for assisted conception may access medications through specialist pathways even if not meeting standard BMI/comorbidity criteria. This recognizes that obesity impacts fertility treatment success rates.^[9]

Pregnancy Contraindication: Both Mounjaro and Wegovy are contraindicated during pregnancy. Women must use effective contraception during treatment and discontinue medications at least 2 months before attempting conception.^[14]

Menopause and Metabolic Health

Post-menopausal women face increased metabolic challenges:

· Central adiposity increases cardiovascular risk

· Sleep apnoea rates rise after menopause

· Insulin sensitivity declines

These factors increase likelihood of meeting comorbidity criteria. The NHS recognizes menopause as a critical period for metabolic intervention, though no specific BMI adjustments exist.

Private vs NHS: Your Options

When Private Prescription Makes Sense

Given strict NHS criteria, many women explore private options. Private clinics can prescribe based on clinical judgment rather than rigid BMI/comorbidity thresholds, often accepting patients with:

· BMI ≥30 with one comorbidity

· PCOS-related weight gain

· Menopause-related metabolic changes

Important Limitation: NHS GPs cannot continue private prescriptions. Patients switching to NHS must meet NICE criteria and undergo specialist assessment.^[15]

Cost Comparison

NHS Treatment: Free at point of use (England), though Scotland/Wales may have prescription charges

Private Treatment: £150-300/month for medication alone, plus consultation fees. Some digital health platforms offer bundled support packages.

Digital Health Integration: Telemedicine platforms like Sheba Health can provide:

· Eligibility assessment and documentation

· Specialist referral support

· Ongoing monitoring and lifestyle coaching

· Coordination between private and NHS pathways

What to Expect During Treatment

Treatment Duration and Monitoring

NICE guidelines recommend maximum 2-year treatment courses, though extension is possible with specialist approval. Patients undergo rigorous monitoring:^[15]

Wegovy Protocol:

· 6-month titration phase (0.25mg → 2.4mg weekly)

· 12-month maintenance

· Discontinuation if <5% weight loss after 6 months at maximum tolerated dose^[11]

Mounjaro Protocol:

· Similar titration structure

· Ongoing specialist review at 12, 18, and 24 months^[11]

· Transition to primary care after stabilization (for eligible patients)

Side Effects and Support

Common side effects include nausea, vomiting, and gastrointestinal discomfort. NHS specialist services provide:

· Dose adjustment support

· Dietary guidance to minimize side effects

· 24/7 advice lines^[11]

NICE's new guidelines emphasize post-treatment support to prevent weight regain, including tailored action plans and community fitness access.^[16]

Future of NHS Weight Loss Treatment

NHS England is implementing a phased rollout over three years:^[10]

Cohort 1 (2025-26): BMI ≥40 + 4+ comorbidities
Cohort 2 (2026-27): BMI 35-39.9 + 4+ comorbidities
Cohort 3 (2027-28): Broader criteria anticipated

This staged approach aims to manage costs (£1,000-1,500 per patient annually) while building specialist service capacity. For women currently ineligible, monitoring these expansions is crucial.

Frequently Asked Questions

Q: Can my GP prescribe Mounjaro or Wegovy directly?
A: Only if you meet strict criteria (BMI ≥40 + 4+ comorbidities for Mounjaro) and your practice participates in the phased primary care rollout. Most prescribing occurs through specialist weight management services.^[1][13]

Q: Does PCOS count as a comorbidity for NHS eligibility?
A: PCOS itself isn't listed, but its metabolic consequences (type 2 diabetes, dyslipidaemia, hypertension) do count. Ensure these are formally diagnosed.^[4]

Q: How long is the NHS waiting list for specialist weight management?
A: Varies by region, typically 3-12 months. Meeting eligibility criteria doesn't guarantee immediate access due to service capacity constraints.^[10]

Q: Can I switch from private to NHS prescription?
A: Only by meeting NICE criteria and undergoing specialist assessment. NHS GPs cannot continue private prescriptions.^[15]

Q: Are there BMI adjustments for menopausal women?
A: No specific menopause adjustments exist, but ethnicity-based reductions (2.5 kg/m²) apply regardless of menopausal status.^[9][1]

Conclusion: Navigating Your Path Forward

Accessing Mounjaro or Wegovy through the NHS requires navigating stringent eligibility criteria designed to prioritize patients with the highest medical need. For women with severe obesity and multiple metabolic complications, these medications represent a valuable tool within a comprehensive weight management strategy.

Key Takeaways:

· Mounjaro demands BMI ≥40 plus four comorbidities, limiting initial access to approximately 220,000 patients nationally^[1][3]

· Wegovy offers broader eligibility (BMI ≥35 with one comorbidity) but remains restricted to specialist services^[2]

· Women's health conditions like PCOS can indirectly qualify through secondary metabolic complications^[4]

· Phased expansions over 2026-2028 may widen access, particularly for Mounjaro^[10]

Digital health platforms can streamline the journey by providing eligibility assessments, specialist referral navigation, and integrated lifestyle support—bridging the gap between NHS capacity constraints and patient needs. As NHS England continues expanding access, staying informed about evolving criteria and regional implementation variations remains essential for women seeking these transformative treatments.

⁂

1. https://crossstreethealthcentre.nhs.uk/news/mounjaro-prescriptions-for-weight-loss-nhs-eligibility-update/

2. https://healthmedia.blog.gov.uk/2023/09/04/accessing-wegovy-for-weight-loss-everything-you-need-to-know/

3. https://www.coltonmill-thegrange.nhs.uk/2025/07/02/mounjaro-prescriptions-for-weight-loss-nhs-eligibility-update/

4. https://obesityhealthalliance.org.uk/2023/03/08/the-oha-welcomes-nice-guidance-on-semaglutide-for-managing-overweight-and-obesity/

5. https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/tablets-and-medication/glp-1/mounjaro

6. https://www.bartonfamilypractice.nhs.uk/2025/06/25/guidance-on-eligibility-for-tirzepatide-mounjaro/

7. https://www.doskimedicalpractice.nhs.uk/mounjaro-prescriptions-for-weight-loss-nhs-eligibility-update-further-update/

8. https://medicinesmanagement.doncasterccg.nhs.uk/wp-content/uploads/2024/02/Semaglutide-Wegovy-_holding_statement-07_02_242-003.pdf

9. https://www.selondonics.org/wp-content/uploads/SEL-Interim-Policy-Access-to-Weight-Management-medicines-May-2025-2.pdf

10. https://www.midandsouthessex.ics.nhs.uk/health/staying-well/healthy-weight/weight-management-services/access-to-tirzepatide-for-weight-management/

11. https://rightdecisions.scot.nhs.uk/media/gepn1ini/use-of-wegovy-obesity-protocol-for-adtc-v2.pdf